This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medical Product Stocks May 8 Earnings List: HSIC, PEN & More
by Urmimala Biswas
An important component of the broader Medical sector, the Medical Product space consistently grabs attention owing to a string of upsides.
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.
Penumbra (PEN) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
Penumbra (PEN) sees strong growth across all geographical regions and product lines in Q4.
Is a Surprise Coming for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Key Factors to Influence Penumbra's (PEN) Earnings in Q4
by Zacks Equity Research
Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.
Penumbra (PEN) Forms JV on Virtual Reality in Health Space
by Zacks Equity Research
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
Why Penumbra (PEN) Might Surprise This Earnings Season
by Zacks Equity Research
Penumbra???s (PEN) favorable Zacks Rank and positive ESP enhance its potential for a beat.
Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?
by Zacks Equity Research
In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.
Key Factors to Influence PerkinElmer's (PKI) Q3 Earnings
by Zacks Equity Research
PerkinElmer's (PKI) divestiture of the Medical Imaging segment in the last quarter is expected to impact earnings this season.
Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health (CVS) is expected to post another quarter of solid top-line performance on the back of gains from the Pharmacy Services segment.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) is positioned to deliver solid results in Q1 on the back of the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.
What's in Store for Penumbra (PEN) Stock in Q3 Earnings?
by Zacks Equity Research
Penumbra (PEN) is expected to gain from strong performance by its neuro and peripheral vascular arms in Q3.
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
by Zacks Equity Research
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.
Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.
Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More
by Zacks Equity Research
Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.
Is a Surprise in Store for Penumbra (PEN) in Q2 Earnings?
by Zacks Equity Research
Penumbra's (PEN) escalating costs and expenses may keep margins under pressure in the yet-to-be-reported second quarter.
Penumbra (PEN) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Penumbra, Inc. (PEN), headquartered in Alameda, CA, scaled a new 52-week high of $91 on Jun 26, eventually closing a little lower at $86.95.
Penumbra (PEN) Q1 Loss Wider than Expected, View Intact
by Zacks Equity Research
Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More
by Zacks Equity Research
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.
Can Penumbra (PEN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Penumbra Inc. (PEN) is slated to release first-quarter 2017 results on May 9, after market close.
Owens & Minor (OMI) Reaffirms Tepid 2017 Financial Guidance
by Zacks Equity Research
Owens & Minor Inc. (OMI) outlined its new strategic plan and reaffirmed the financial guidance.
TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
TrovaGene Inc. (TROV) reported loss of 31 cents per share in the fourth quarter of 2016, 2 cents wider than the Zacks Consensus Estimate.
Cogentix (CGNT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Cogentix Medical, Inc. (CGNT) reported adjusted loss of 14 cents per share in the fourth quarter of 2016.